Duyuru • May 19
Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025 Biotechnology Assets, S.A., Annual General Meeting, Jun 18, 2025. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain Reported Earnings • May 19
Full year 2024 earnings released Full year 2024 results: Revenue: €2.97m (down 24% from FY 2023). Net loss: €2.92m (down 285% from profit in FY 2023). New Risk • May 14
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended June 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (19% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported June 2024 fiscal period end). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€20.2m market cap, or US$22.6m). New Risk • Apr 11
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 16% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (21% average weekly change). Minor Risks Shareholders have been diluted in the past year (16% increase in shares outstanding). Revenue is less than US$5m (€3.4m revenue, or US$3.8m). Market cap is less than US$100m (€21.2m market cap, or US$24.1m). New Risk • Oct 23
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (1.2% operating cash flow to total debt). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2023 fiscal period end). Shareholders have been diluted in the past year (11% increase in shares outstanding). Revenue is less than US$5m (€3.9m revenue, or US$4.2m). Market cap is less than US$100m (€19.5m market cap, or US$21.1m). Duyuru • May 21
Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024 Biotechnology Assets, S.A., Annual General Meeting, Jun 19, 2024. Location: hotel melia madrid serrano, calle claudio coello 139., madrid Spain New Risk • Apr 11
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended December 2022. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported December 2022 fiscal period end). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Shareholders have been diluted in the past year (6.5% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.2m). Market cap is less than US$100m (€21.3m market cap, or US$22.9m). New Risk • Dec 31
New major risk - Revenue and earnings growth Revenue has declined by 9.9% over the past year. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If revenues are declining, then it is difficult for the company to prevent its earnings from declining as well. A trend of falling revenue can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Revenue has declined by 9.9% over the past year. Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (6.8% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.3m). Market cap is less than US$100m (€22.8m market cap, or US$25.2m). New Risk • Oct 29
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risk Share price has been highly volatile over the past 3 months (18% average weekly change). Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (14% increase in shares outstanding). Revenue is less than US$5m (€3.0m revenue, or US$3.1m). Market cap is less than US$100m (€23.7m market cap, or US$25.0m). Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Javier Luz was the last director to join the board, commencing their role in 2021. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Reported Earnings • Nov 03
First half 2021 earnings released The company reported a decent first half result with improved earnings and profit margins, although revenues were weaker. First half 2021 results: Revenue: (down 100% from 1H 2020). Net income: (up €10.0m from 1H 2020). Profit margin: (up from net loss in 1H 2020). The move to profitability was driven by lower expenses. Is New 90 Day High Low • Feb 16
New 90-day high: €1.20 The company is up 206% from its price of €0.39 on 18 November 2020. The German market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is up 17% over the same period. Is New 90 Day High Low • Jan 09
New 90-day high: €0.97 The company is up 425% from its price of €0.18 on 09 October 2020. The German market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is flat over the same period. Is New 90 Day High Low • Dec 08
New 90-day high: €0.50 The company is up 4.0% from its price of €0.48 on 09 September 2020. The German market is up 3.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Biotechs industry, which is down 11% over the same period. Duyuru • Oct 08
Kartesia Advisor LLP acquired 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. (BME:ADL) and Black Toro Capital LLP. Kartesia Advisor LLP acquired 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. (BME:ADL) and Black Toro Capital LLP on October 7, 2020. The agreement also includes a new tranche of €5 million made available at closing by Kartesia for the general corporate purposes of ADL, a commitment by the shareholders to approve a capital increase of at least €10 million to be completed before year-end, pro rata of the stake of each party, and the A&E (an amend and extend facility) of the senior financing. With immediate effect, ADL Biopharma will operate as an independent entity from ADL Bionatur Solutions. The Board of Directors has been expanded to 5 seats with the appointment of 3 new independent Directors: Raúl Crespo (Deloitte, Oquendo, KPMG), Ignacio Urbelz (Calidad Pascual, Vivesoy, HP) and Mirco Iwan (Capua Bioservices, Eismann), adding relevant expertise in key areas such as finance, operations and sales.
Kartesia Advisor LLP completed the acquisition of 51% stake in ADL Biopharma from ADL Bionatur Solutions, S.A. (BME:ADL) and Black Toro Capital LLP on October 7, 2020. Duyuru • Jul 17
ADL Bionatur Solutions, S.A. Auditor Raises 'Going Concern' Doubt ADL Bionatur Solutions, S.A. filed its Annual on Jun 22, 2020 for the period ending Dec 31, 2019. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern. 